Fennec Pharmaceuticals Inc (FENC)

[BioSpecialist]

ADHXF (MC $19 M) 2x Phase 3 results in June 2014 .

Adherex (AHX.TO) (ADHXF) is definitely one of the cheapest Cancer Play with 2 Phase 3 who pending results in June .

2x Phase 3 results in june 2014 .

STS is a chemoprotectant being developed by Adherex to reduce or prevent hearing loss in oncology patients resulting from treatment with platinum-based chemotherapy drugs.

Drug has Orphan Drug Status and there is no approved treatment for this Indication . Market Cap of $19 M is really a big big joke .

Target $8-10 within 12 months if positive phase 3 outcome in june .


Adherex (AHX.TO) (ADHXF)

Market Cap: $19 M
Cash $1.7 M
Price: $0.76

Shares Out: 29.1 M
Float: 7 M


Präsentation Jan 2014
http://adherex.com/wp-content/uploads/2014/02/Adherex-Corporate-Presentation-January-2014.pdf


Two late stage oncology clinical products: Sodium Thiosulfate (STS) and
Eniluracil (EU)

–STS:Data from two Phase 3 trials expected to be presented at ASCO in Q2 2014
»pending favorable outcome from both studies-file NDA
–EU: pending partnering discussions- advance to Phase 3

Phase 3 trial conducted by SIOPEL6 in children with liver cancer 86/102 patients enrolled with interim safety data expected to be presented at ASCO Q2 2014

No approved treatment: Adherex has been developing STS since 2003
•Received Orphan Drug Designation in 2004 with 7.5 years exclusivity upon approval


Study ACCL0431: "A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children", conducted by the Children's Oncology Group, finished enrollment of 135 patients in 1Q 2012. These patients had been previously diagnosed with one of five rare childhood cancers typically treated with intensive cisplatin therapy, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. The final results from the study are expected to be submitted for presentation at the American Society of Clinical Oncology (ASCO) in June of 2014. Preliminary study data is not available to Adherex for public disclosure.


SIOPEL 6: "A Multicenter Open Label Randomized Phase III Trial of the Efficacy of Sodium Thiosulfate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma" is being conducted by The International Childhood Liver Tumor Strategy Group, SIOPEL. As of this date, the study has enrolled 83 out of the planned 102 patients. SIOPEL 6 is being conducted in standard risk hepatoblastoma patients where the effectiveness of the platinum treatment is known to be very high. The first three interim safety analyses were conducted after 20, 40, and 60 patients, and in each case, the Independent Data Monitoring Committee recommended continuation of the study. An interim efficacy analysis is planned in the first half of 2014 with the possibility for early completion of trial if there is greater than expected difference in hearing loss between the treatment arms. Interim data are expected to be submitted for presentation at the American Society of Clinical Oncology (ASCO) in June of 2014.